The majority of published works that focused on the role of γ-H2AX foci as a biomarker to predict tumour radiosensitivity [38,39] were conducted in vitro or in HNSCC tumour xenograft models and not in a clinical study. This evidence concerns the gene H2AX and head and neck squamous cell carcinoma.